An ETF That can Quiet Biotech Boo Birds

Since reaching all-time highs on March 19, the three largest biotech exchange traded funds are off 4.4% with the SPDR S&P Biotech ETF (NYSEArca: XBI) ranking as the worst offender of the trio with a loss of 5.7%. XBI’s recent struggles illustrate the ETF’s risk/reward proposition. As an...